Application of Nanoparticles for Targeting G Protein-Coupled Receptors

Xin Ma †, Yunfang Xiong † and Leo Tsz On Lee *

Centre of Reproduction Development and Aging, Faculty of Health Sciences, University of Macau, Taipa, Macau, China; florazgnd@gmail.com (X.M.); yb77617@connect.umac.mo (Y.X.)
* Correspondence: LTOLee@umac.mo; Tel.: +853-8822-4929
† These authors contributed equally to this work.

Received: 30 May 2018; Accepted: 4 July 2018; Published: 10 July 2018

Abstract: Nanoparticles (NPs) have attracted unequivocal attention in recent years due to their potential applications in therapeutics, bio-imaging and material sciences. For drug delivery, NP-based carrier systems offer several advantages over conventional methods. When conjugated with ligands and drugs (or other therapeutic molecules), administrated NPs are able to deliver cargo to targeted sites through ligand-receptor recognition. Such targeted delivery is especially important in cancer therapy. Through this targeted cancer nanotherapy, cancer cells are killed with higher specificity, while the healthy cells are spared. Furthermore, NP drug delivery leads to improved drug load, enhanced drug solubility and stability, and controlled drug release. G protein-coupled receptors (GPCRs) are a superfamily of cell transmembrane receptors. They regulate a plethora of physiological processes through ligand-receptor-binding-induced signaling transduction. With recent evidence unveiling their roles in cancer, GPCR agonists and antagonists have quickly become new targets in cancer therapy. This review focuses on the application of some notable nanomaterials, such as dendrimers, quantum dots, gold nanoparticles, and magnetic nanoparticles, in GPCR-related cancers.

Keywords: G protein-coupled receptor (GPCR); cancer; nanoparticles (NPs); dendrimers; quantum dots (QDs); gold nanoparticles (AuNPs); magnetic nanoparticles (MNPs)

1. GPCR Activation and GPCRs in Cancer

G protein-coupled receptors (GPCRs) are membrane receptors that make up the largest family of cell surface receptors of the human genome [1]. GPCRs are also called seven-transmembrane (7TM) receptors because of the common structural motif shared by their family members. Based on sequence homology and phylogenetic data, human GPCRs are classified into six groups: Class A comprises of rhodopsin receptors; class B has two subclasses—secretin receptors (B1) and adhesion receptors (B2); class C comprises of glutamate receptors; class F comprises of frizzled receptors, and class T comprises of taste two receptors [2]. GPCRs can convert foreign stimuli, ranging from particles as small as protons to large proteins, into intracellular signals through different mechanisms [3,4]. In the classical model of receptor activation, GPCR signaling is mediated by guanine nucleotide-binding proteins (G proteins) upon ligand-receptor binding. G proteins associated with GPCRs are heterotrimERIC and composed of three subunits: α-, β- and γ-. In the basal state, Gα is anchored to the inner surface of cell membranes and bound to GPCR, guanosine diphosphate (GDP), Gβ and Gγ. When a ligand activates GPCR, an exchange of GDP to guanosine triphosphate (GTP) takes place. This event results in a monomeric GTP bound form of Gα, a Gβγ dimer, and the dissociation of the Gα-GTP from the receptor. The freed Gα-GTP monomers and Gβγ dimers can regulate effector enzymes, such as adenyl cyclases, phospholipases, and ion channels, which in turn induces a series of downstream signaling cascades [5].
When GPCR is activated, it undergoes conformational changes. The G protein-coupled receptor kinases (GRKs) recognize activated receptors and phosphorylate GPCRs on specific sites, while β-arrestins are recruited for receptor desensitization (dissociation of G protein and GPCR). In contrast to the classical view, a “biased activation” mode was proposed, upon uncovering the evidence of GPCR activation via β-arrestin. Arrestins were originally recognized for their roles in GPCR desensitization. In the biased activation mode, GPCRs recruit either the G protein-dependent pathways, or the β-arrestin-dependent pathways, where β-arrestin mediates a range of GPCR signaling transductions. The molecular mechanism of biased activation is not fully understood; however, it is speculated that both GPCR conformational stabilization and downstream pathways are different between G protein-biased ligand activation and arrestin-biased ligand activation [4,6]. In addition to the two GPCR activation modes mentioned above, a “transactivation” mode has also been proposed. The traditional transactivation refers to the GPCR ligands activating receptor tyrosine kinases (RTKs), such as GPCR agonists activating epidermal growth factor receptors (EGFRs) and platelet-derived growth factor receptors (PDGFRs). The underlying mechanisms of this activation involve the generation of RTK ligand precursors after GPCR activation [7], or the formation of a GPCR-RTK receptor signaling complex, where activated G protein subunits can be used by RTKs and trigger a RTK downstream signaling cascade [8,9]. On the other hand, it is established that the crosstalk between the two receptor families is bidirectional. The mechanisms of GPCR transactivation are similar to those of RTK transactivation, which involve the synthesis of cognate GPCR ligand or GPCR-RTK complex formation [7]. The expression level of the Gα subunits may influence the biased signal of GPCR and even the transactivation of RTKs [10]. In the naïve state, the level of Gα expression affects not only Gα signalling but also the co-expressed receptor within different membrane domains. These evidences proposed a unique model to control for RTK activation via targeting GPCR complexes. This crosstalk between RTK and GPCR signalling systems regulates several cellular processes; the dysfunctional signal integration between the two receptors may sometimes result in a variety of disease states, such as cardiovascular and renal disorders, obesity, metabolic syndrome, type diabetes mellitus, cancer, etc. The understanding of GPCR activation is fundamental for targeted cancer therapy. However, due to the complexity of the biased activation and GPCR transactivation, this review only covers GPCR targeted therapy based on classical ligand-receptor binding.

GPCRs regulate nearly all the physiological processes, playing important roles in multiple systems, such as the immune system, cardiovascular system, neuron system, reproductive system and sensory system. GPCR dysfunction causes a variety of diseases, including diabetes, hypertension, Alzheimer’s disease, anxiety, asthma and cancer [11]. It is now understood that mutations in GPCR genes and irregularities in GPCR signaling pathways can cause carcinogenesis and cancer progression [12,13]. Notable GPCRs linked to cancer include lysophosphatidic acid receptors (LPARs), chemokine receptors, gastrin-releasing peptide receptors (GRPRs) and angiotensin II (ANGII) receptors. Lysophosphatidic acid (LPA) is a glycerophospholipid, and widely regarded as a cancer inducer. Its physiological role includes cell proliferation, cell migration, DNA synthesis and cytokine production. Alterations in LPA circulation profiles and LPAR expression levels can lead to cancer genesis and progression, which are demonstrated in ovarian, thyroid, colon, breast and pancreatic cancer [14–16]. For example, the study by Yu et al. revealed that a majority of ovarian cancer cells aberrantly overexpress LPAR2 and LPAR3 [16]. The roles LPARs play in promoting cancer survival and growth, and inhibiting migration and invasion of cancer cells, are well documented. LPRAs stimulate multiple downstream signaling pathways such as the MAPK/ERK pathway, P13K-Akt pathway and Rho-signaling pathway. Several LPAR antagonists are currently being investigated for cancer treatment. For instance, drugs based on isoxazole and thiazole are being used to treat pancreatic cancer metastasis [12]. Chemokines are chemotactic cytokines. They function in cell–cell interactions and cell migration. High levels of chemokine production can induce aberrant chemokine receptor activation and promote tumor growth and metastasis. Among the fifty identified chemokines, CXCL1-3, CXCL8, CCL2 and CCL5 are thought to be linked to tumor progression. Chemokine receptor 4 (CXCR4) is believed to
be a driver of tumor metastasis and is overexpressed in ovarian cancer cells, breast cancer cells and acute lymphoblastic leukemia [1,13,17]. Various drugs targeting CXCR4 activation and downstream signaling have been developed. For example, the CXCR4 antagonist plerixafor (AMD-3100) inhibits angiogenesis within cancer xenografts in mice and is being tested in clinical trials. In another example, treatment with PIM kinase inhibitors efficiently blocks CXCR4-induced migration by receptor dephosphorylation [18]. GRP, also called mammalian bombesin (BBN), functions as a neuropeptide and a growth factor. Both GRPs and GRPRs are found overexpressed in many cancers, including gastric, lung, prostate, and breast cancer. In a study conducted on 1432 primary breast cancer samples, GRPRs were found to be overexpressed in over 75% of the cases. Interestingly, when GRPRs were overexpressed in breast tumors, a high level of GRPR expression was also detected in metastatic lymph nodes in about 95% of the cases [19]. Activated GRPRs can induce the MAPK/ERK signaling pathway and Rho-signaling pathway [20]. The high binding affinity of GPRP towards cancer cells makes it a promising candidate for targeting cancer cells. GRPR antibody 2A11 is currently in clinical use for lung cancer treatment. Antagonist RC-3095 is able to inhibit cancer proliferation in various cancer cells in vivo and in vitro and shows strong potential for cancer therapy. Unfortunately, a clinical trial of this antagonist failed, owing to local toxicity induced by its administration [21]. ANGII is a peptide hormone and regulates the renin-angiotensin system (RAS). Studies have shown that the upregulation of ANGII leads to the acquisition of malignancy in human cancers [22]. ANGII activates two types of ANGII receptors: AGTR1 and AGTR2. AGTR1 is overexpressed in various cancers, including breast cancer, pancreatic cancer, gastric cancer and glioblastomas [23]. ANGII is able to activate many types of signaling transduction via AGTR1 binding, including IP3/Ca^{2+} signaling, MAPKs, Src kinases and NF-κB pathways [12]. Treatment with AGTR1 antagonists, such as losartan and candesartan, show anti-tumor effects [24,25]. However, owing to ANGII’s role in the RAS, administration of the AGTR1 inhibitor might induce ventricular dysfunction and requires caution.

2. Nanoparticles

While the traditional methods for treating metastatic cancers, such as chemotherapy and biological therapy, are effective at killing cancerous cells, they also cause irreversible damage to normal tissues. The need for new anticancer drugs with targeted delivery has demanded a paradigm shift in cancer therapy, away from conventional methods [26]. In the meantime, recent advances in nanotechnology—for example, the development of nanomaterials and nanocarriers—have been applied to the realm of medicine, leading to the development of new drug delivery systems. Engineered nanoparticles (NPs) range in size from 1 to 100 nm. They are able to deliver cargos, such as drugs, siRNAs (short interfering RNAs) and DNAs, to the site of action without disturbing other tissues. Moreover, some of them can be delivered into the targeted cells, where they induce cell death by endocytosis. Due to the potential usage of NPs for a wide range of medical applications, a variety of nanoparticles are now being developed. The benefits of using NPs to deliver chemotherapeutic agents include improved drug solubility, stability, prolonged circulation, specific cell targeting, controlled drug release, and limited cytotoxicity, (on account of their sizes and physicochemical properties) [27–29]. In this review, we highlight the mechanism of targeted cancer therapy and the recent applications of nanoparticles in the treatment of GPCR-related cancers.

2.1. Passive Targeting and Positive Targeting

The first generation of nanomedicine in cancer therapy is based on the discovery of the enhanced permeability and retention (EPR) effect, which is used to describe the “leaky” environment of tumors. Increased cytokines, angiogenesis and other cellular factors associated with tumors, cause intratumoral vessels to lose their normal membrane lining, resulting in enhanced permeability. The pore size in tumor vessels is 100–780 nm in diameter, while the pore size in normal vessels is 5–10 nm in diameter [26]. This huge disparity in size permits the passage of certain sized drugs and their long-term accumulation. The EPR effect is exploited in cancer therapy, and allows drug
circulation and accumulation, preferably in the microenvironment of the tumor. Drugs are then released by pH-dependent hydrolysis into the tumor tissue, or by endosome-mediated hydrolysis and enzymolysis [30]. Passive targeting is used by most of the clinically available anticancer nanotherapies. However, the application of passive targeting has some limitations. First, tumor cell subpopulations within the disease sites exhibit variations in phenotype and function. This is called “tumor heterogeneity” and it can lead to different cell responses towards the same drug within the target sites, and causes inconsistent outcomes [31]. Second, interstitial pressure presented in tumor sites negatively affects drug access and distribution [29]. Third, organs such as the liver and spleen have inherent endothelial fenestrations, and hence, can be accessed by drugs that do not target these organs [27]. To overcome these disadvantages, a second generation of nanomedicine, based on active targeting, is being engineered, with a focus on accurate drug delivery and enhanced efficiency.

In active targeting, the high affinity between ligands and receptors is utilized in NP delivery to achieve preferential targeting of cancer cells that express or overexpress certain receptors. The ligands are conjugated to nanocarriers and are delivered to the surface of targeted cells via molecular recognition. Similarly, antibodies can also be attached to NPs, and are transported to antigenic cell surface areas. It should be noted that in therapies used to treat solid tumors, active targeting is started after passive targeting, to allow adequate drug accumulation at the target sites [32]. It is also worth mentioning that, in the absence of specific ligands, NPs are capable of carrying out intermembrane trafficking. Palanka et al. reported that gold nanorods can attach to cell membranes via ion charges, and enter lipid membranes through transient pores formed by the generation of local heat [33].

2.2. Drug Design

The design of NPs depends on the purposes of application and types of action. To deliver drugs via positive targeting, NPs are often coated with biopolymers and conjugated with ligands. Drugs are either encapsulated or attached to the surface of NPs covalently in their monomeric or oligomeric forms [27,34,35]. For the drug-conjugated NPs to be delivered to the target sites, they must escape recognition and clearance by the reticuloendothelial system (RES). To achieve this, surface modulations, such as polyethylene glycol (PEG) coating or poly (HPMA) coating, are applied. The hydrophilic coating helps the NPs to escape macrophage clearance and avoid contact with plasma proteins, thus further preventing elimination by phagocytes [26].

Physicochemical properties, such as size, shape, thermal conductivity, magneticity and surface charges are often taken into consideration when designing NPs, as such properties affect how the NPs function as diagnostic tools, carriers or imaging agents. For example, smaller NPs move faster in the tumor interstitial matrix, and hence for chemotherapeutics, the size of NPs is restricted to a maximum of several nanometers [29]. The size of NPs also affects their cellular uptake rate and rate of degradation. As another example, compared to spherical NPs, nanorods are better candidates as contrast agents. This is because spherical NPs have absorption and scattering peaks in the visible region, whereas the absorption and scattering peaks of nanorods are in the near-infrared region, where the light provides broader absorption and scattering cross-sections, and deeper penetration [36]. Surface charge also plays a critical role in gene delivery. Cationic polymers are often chosen as DNA carriers. This is because positively charged polymers bind easily to the negatively charged cell membranes, making access to inside the cell possible. In addition, after enzymic actions, DNA-polymers are cleaved to DNA and polyamines. Polyamines attract hydrogen ions and chloride ions to the endosomes, which triggers endosome osmotic swelling and lysis, and prevents DNA degradation, thus allowing DNA to enter the nucleus [37].

2.3. Dendrimers

Dendrimers are covalently synthesized monodisperse globular molecules embodying three parts: a core, a hyperbranched mantle and functional terminal groups [38]. The structure of the dendrimers resembles a tree, where the layers surrounding the core are connected by branching units. Each layer
of dendrimer is called a generation; the core is known as G0, the first layer outside the core as G1, the second layer as G2, and so on (Figure 1). For each generation of amplification, the density of the outermost space increases. Therefore, dendrimers cannot expand unlimitedly [39]. The empty cavities in dendrimers are used to capture drugs or other small molecules. Thus, dendrimers have a high loading capacity. Furthermore, the high density of functional groups on the surface of the dendrimers makes it possible to carry multiple ligands to form multivalent ligands, which have more favorable pharmacodynamic properties than their monomeric form [40]. So far, many materials have been developed for dendrimer synthesis, such as polyamidoamine (PAMAM), polypropyleneimine (PPI), poly-L-lysine (PLL), PEG and poly-glycerol. Of these, PAMAM and PPI are more widely studied [38].

![Figure 1. Structure of dendrimer. The blue sphere (G0) is the core of the dendrimer. Branching units are marked in orange. Starting from the core, the generations are extended and labeled as G1–G4. The outermost layer contains the dendrimer’s terminal groups (green).](image)

**Figure 1.** Structure of dendrimer: The blue sphere (G0) is the core of the dendrimer. Branching units are marked in orange. Starting from the core, the generations are extended and labeled as G1–G4. The outermost layer contains the dendrimer’s terminal groups (green).

GPCR Ligand-Dendrimer (GLiDe) conjugates targeting adenosine receptors (ARs) are the first PAMAM dendrimers synthesized. ARs are a subfamily of Rhodopsin-like GPCRs that comprise four subtypes: A1, A2A, A2B and A3. Each subtype has a different expression pattern in the body and different signaling pathways and performs different functions. A1ARs, for example, are widely located in the synaptic regions in neurons, whereas A2ARs localize highly in presynaptic regions in the hippocampus. These two receptors differ from regulators of neurotransmitter release. ARs are also involved in inflammation, Parkinson’s disease and cancer [41,42]. Owing to the abundance and varied functions of the subtypes, nanocarriers with good selectivity and sensitivity (targeted to certain type(s) of ARs) are required.

Owing to improved selectivity and an affinity to receptors [43], multivalent GLiDe conjugates display enhanced pharmacokinetic and pharmacodynamic properties. The first multivalent dendrimer to activate a GPCR signaling pathway was developed by Kim et al. [44]. The dendrimer scaffold included a G3 PAMAM dendrimer as its backbone, multiple copies of A2AAR agonist CGS21680, and a fluorophore. Studies have shown that PAMAM–CGS21680 conjugates have the ability to inhibit ADP-induced platelet aggregation, a known function of A2AAR agonists. The dendrimers were found to be internalized into the platelets via receptor-mediated internalization. Following this study, a G3 PAMAM carrier, attached to a fluorophore and multiple copies of A2AAR agonists (DITC-APEC), was synthesized. This conjugate showed improved conformational flexibility, ligand-receptor affinity, selectivity, (compared to PAMAM–CGS21680), and also displayed A2AAR agonistic behavior in the platelet aggregation assay. However, this study also revealed that, in addition to binding to A2AAR, the dendrimers were also bound to A3AR; and receptor-mediated internalization was not detected [45].

Even with these disadvantages, this pioneering research marked the discovery of GLiDe applications
targeting GPCRs and served as a prototype for the treatment of AR-related diseases. Other studies of GliDe conjugates targeting AR and purinergic P2Y receptors subsequently followed [46,47]. Notably, in an attempt to target heteromeric GPCR aggregates, Tosh et al. demonstrated the first example of using the same dendrimer carrier to target two different GPCRs (A3 and P2Y14) [48].

2.4. Quantum Dots

Originating from early efforts of the fluorescent approach to visualize receptors in the 1970's, scientific advances have now made it possible to monitor a series of real time events of ligand–receptor interactions in living cells [49]. Among some notable advances, quantum dots (QDs) stand out due to their unparalleled fluorescence properties. QDs are also known as nano-quantum dots, semiconductor quantum dots or semiconductor nanocrystals. They are a special type of inorganic crystal with a wide excitation wavelength range, narrow and symmetrical emission wavelength, and small overlapping between excitation and emission wavelengths [49,50]. QDs possess several unique properties that make them outstanding candidates as bioimaging material. For example, their emission wavelength can be adjusted by controlling their size and composition, and the QDs of the desired wavelength can be synthesized arbitrarily [51]. In addition, QDs have considerable fluorescence intensity and stability, with no light-fading phenomenon [52]. With the rapid developments in material science and biomedical science, the use of QDs in drug screening, cell tracing, immunoassay and rapid diagnosis offers great potential [53–55].

Generally speaking, two main methods are used to couple QDs with biological molecules. The first method involves covalent bonding, achieved by attaching the surface of the QD with a carboxyl group, an amino group or an epoxy group. Covalent binding offers high stability and binding efficiency within a broad range of pH and ions strengths. Although the coupling procedure is relatively complicated, it can be applied to a wide range of research areas, such as antigen–antibody recognition and in vivo labeling [56]. The second coupling method involves an electrostatic adsorption method, where the charged QDs are coupled with the oppositely charged biomolecules through electrostatic interactions. This QD coupling approach is utilized in biosensors [57]. In 2005, Young and Rozengurt reported that GPCRs can be labeled by QDs in multiple cell lines. In this research, they conjugated biotinylated BBN and ANGII with streptavidin-coated QD nanocrystals with emission maxima of ~665 nm (QD655), in order to detect the interaction between GPCRs and their ligands. They successfully monitored cell-associated fluorescence of QD655-BBN in living cells that express the BBN receptor, and of QD655-ANGII in cells expressing AGTR1. Furthermore, to investigate the performance of the QD label, they compared the strength of the signals produced by QD655-ANGII and the Cy3-labeled ANGII. QD655-ANGII exhibited much stronger luminescence and greater stability [53]. Going forward to 2015, Hennig et al. investigated the multivalent binding between QD-ANGII and its receptor. This study found that chemically modulated QD-ANGII bound to AGTR1 in a much higher affinity, compared to native ANGII in AGTR1-expressing cells, but did not bind to AGTR1-negative cells, indicating that nanoparticles bind with AGTR1 specifically and in a multivalent fashion [58]. In conclusion, QDs show great potential in cell-labeling applications, and immense potential in GPCR and cancer studies. Other than AGTR1, Fichter et al. developed a strategy using QDs to investigate the role of endosomal trafficking in serotonin receptor signaling pathways in 2010 [59]. Serotonin receptors belong to the GPCR family, which play an important role in regulating anxiety and depression-related signaling pathways. To monitor serotonin internalization and endosomal trafficking, the researchers used the biotinylated anti-HA-conjugated streptavidin QD655 to interact with the HA-tagged serotonin receptor subtype 1A (HA-5-HT1A). Both of the internalization and recycling pathways relating to 5-HT1A were successfully detected.

2.5. Gold Nanoparticles

The use of gold nanoparticles (AuNPs) in cancer diagnosis and treatments has been extensively investigated [60–63]. Their unique physicochemical properties make them valuable assets in a wide
range of applications. First, the size of AuNPs enables them to circulate freely in the vascular system, for passive targeting. Second, AuNPs can be surface modified by the attachment of hydrocarbon chains and a variety of functional groups. This makes AuNPs an excellent multifunctional carrier. For example, AuNPs bind strongly to thiol groups due to the high affinity between sulfur and gold. Therefore, molecules containing thiol groups can be used to bridge AuNPs and a number of functional molecules, such as certain drugs, fluorescent dyes, amino acids and proteins. Thiocapped biomolecules can also bind to the surface of AuNPs directly [64,65]. Additionally, AuNPs have a large surface-area-to-volume ratio, which makes it possible to attach a large number of functional groups to their surface. Furthermore, AuNPs can scatter visible and near-infrared light, and are used as imaging contrast agents. Moreover, their fluorescence-quenching ability is exploited in sensor fabrication [66–68]. Lastly, their surface plasmon resonance property plays versatile roles. In bioimaging, it is utilized in colorimetric sensing [69]. It is also widely used to enhance laser absorption, which leads to many therapeutic applications, such as photothermal cancer therapy, selective protein denaturation, and transmembrane drug delivery. In one study, Xiong et al. demonstrated that the use of gold nanoparticles (AuNPs) in combination with laser beams allowed the generation of water vapor nanobubbles in live cells, which caused membrane pore formation. The pores allowed the passage of macromolecules into cytoplasm without inducing noticeable cytotoxicity [70]. Other studies also described the delivery of AuNPs into cells [71] and temperature controlled delivery [72].

Jayasekara et al. were the first to synthesize AuNP carriers with non-peptide GPCR agonists [73]. In their study, several functionalized, surface-modified, hydrophilic, AuNPs-AR agonist/antagonist conjugates were evaluated for their functions and properties at the cell surface. Those AuNP conjugates showed promising potential as GPCR therapeutic targets as they were found to possess similar biological properties to their monomeric counterparts in terms of specific receptor recognition, binding affinity and receptor-induced cAMP inhibition. In 2009, Nripen et al. created novel designed gold nanorods (GNRs) and BBN conjugates, and successfully delivered them to prostate and breast cancer cells. The synthetized GNR–BBN conjugates proved to be highly stable in various solutions in vitro. Similar to BBN monomers, GNR–BBN conjugates exhibited high affinity towards cancer cells that overexpress GRPRs. Transmission electron microscope (TEM) image analysis and dark-field optical microscopy analysis have confirmed receptor-mediated endocytosis of GNR–BBN internalization [74].

2.6. Magnetic Nanoparticles

The design of the magnetic nanoparticle (MNP) delivery system was based on the attraction between an external magnetic field and the metal or metal oxide compounds that make up the core of MNPs. In the presence of a magnetic source, MNPs can be directed towards, and effectively “trapped” in the targeted sites. Because of their unique magnetic properties, MNPs are popularly used as contrast agents in magnetic resonance imaging (MRI), as nanocarriers, and to induce magnetic hyperthermia. As nanocarriers, external magnets are applied to provide the appropriate magnetic field gradient that allows sufficient dosage accumulation in the targeted area. Drugs or cytotoxic agents can then be released by means of passive targeting, positive targeting, or magnetically [75]. In magnetic hyperthermia therapy, MNPs are remotely controlled by an oscillating magnetic field. When arriving at the tumor sites, MNPs transform electromagnetic energy into heat and selectively kill heat-sensitive cancer cells [76].

Among the classic magnetic materials, such as iron, nickel, cobalt, and their compounds, iron-based MNPs have attracted great attention, owing to their size-dependent magnetic properties and excellent biocompatibility, compared to other magnetic materials [76,77]. Superparamagnetic iron oxide NPs (SPIONs), for example, have been intensively studied and are used in a variety of biological applications. Richard et al. engineered a bimodal imaging tracer using a PEGylated SPION nanoplatrorm. It was chemically modified and bound to a fluorophore and an antibody, against an endothelin receptor (ETA)—a GPCR that overexpressed in a variety of solid tumors. Not only did the SPION conjugates demonstrate effective ETA targeting, showcasing the antibody’s
resuming functionality after conjugation, but they also manifested low toxicity and high stability under physiological conditions. Their excellence as an MRI contrast agent and imaging tracer has also been demonstrated by in vivo experiments in mice [32]. Sanchez et al. investigated cell death induced by iron oxide nanoparticles (IONPs) targeting cholecystokinin-2 receptor (CCK2R). CCK2R is overexpressed in thyroid carcinomas, small-cell lung cancers and gastrointestinal stromal tumors. Both of its ligands, (gastrin and CCK), can activate CCK2R. A synthetic form of gastrin, termed MG, was engineered to have a pharmacophore of gastrin, a CCK C-terminal sequence (used to investigate CCK2R internalization), and an exchanged amino acid sequence (aimed at preventing the accumulation of gastrin in kidney). MG was then conjugated with IONP and a fluorescent label DY647. The fate of the conjugates was subsequently revealed. In cancer cells, they specifically bound to CCK2Rs, and underwent receptor-dependent endocytosis before entering lysosomes. When subjected to an external magnetic field, the internalized NPs caused lysosome leaking, which led to cell death [78]. The mechanism of MNP-induced cell death is illustrated in Figure 2.

![Figure 2. Mechanism of the cell death induced by magnetic particles.](image)

**Figure 2.** Mechanism of the cell death induced by magnetic particles. Functional magnetic nanoparticles (MNPs) recognize the surface receptor by ligand-receptor recognition. Upon binding to the receptor, MNPs are internalized and accumulated in lysosomes. When applying an external alternating magnetic field, lysosomal membranes break, which leads to cell death.

2.7. Others

In addition to the examples mentioned above, other materials that target GPCR-related cancer have been investigated. For example, Fan et al. synthesized unmodified NPs, conjugated with follicle-stimulating hormone polypeptide (FSHP) and anticancer drug PTX, to treat lymphatic metastasis in ovarian cancer therapy. The conjugates were administered to mice injected with ovarian cancer cells. Compared to control groups (NP-PTX and FSHP-NP), FSHP-NP-PTX showed the highest PTX concentration in lymph nodes, the greatest inhibitory effect in cell proliferation, and increased mice survival time. Furthermore, PTX toxicity seemed to be reduced when the PTX was conjugated with NPs [79]. As another example, in an attempt to target GRPRs in prostate cancer, Zhang et al. developed an elastin-like polypeptide (ELP) micellar carrier platform fused with GRP. Specific receptor targeting was achieved, as demonstrated by intracellular calcium release. GPR binding to membrane and NP internalization was also monitored [80]. Table 1 lists some of the more recently discovered NPs and their application in GPCR-related studies.
Table 1. Recent applications of NPs targeting GPCR.

| Nanoparticles | Ligand/Antibody | GPCR | Function | Reference |
|---------------|----------------|------|----------|-----------|
| Dendrimer     | MRS2500 (antagonist) | P2Y(1) | Affinity to receptor (K<sub>i</sub> 23 nM); Inhibiting ADP-promoted human platelet aggregation; Antithrombotic drug | [46] |
|               | XAC (antagonist) | Adenosine receptor (A<sub>2A</sub>AR) | Affinity to receptor (K<sub>i</sub> 3.7 nM); Treating Parkinson’s disease and asthma | [81] |
|               | CGS21680 (agonist) | Adenosine receptor (A<sub>2A</sub>AR) | Affinity to receptor (K<sub>i</sub> 12 ± 6 nM); Activating adenylate cyclase and accumulating cAMP; Inhibiting ADP-promoted human platelet aggregation; Using short PEG chains in nanocarriers targeting ligand-receptor interactions | [82] |
|               | UDPGA-A3AR 3a-G4 PAMAM (agonist) | Both Adenosine receptor (A<sub>3</sub>AR) and P2Y14 | Affinity to receptor (K<sub>i</sub> 39.5 nM to A<sub>3</sub>AR); Inhibiting cAMP cumulation; Antithrombotic drug | [46] |
|               | DITC-APEC (agonist) | Adenosine receptor (A<sub>2A</sub>AR) | Affinity to receptor (K<sub>i</sub> 70 ± 3 nM); Inhibiting ADP-promoted human platelet aggregation; Antithrombotic drug | [45] |
| Nanoparticles       | Ligand/Antibody                      | GPCR                             | Function                                                                 | Reference |
|---------------------|--------------------------------------|----------------------------------|--------------------------------------------------------------------------|-----------|
| Quantum dots (QDs)  | α-melanocyte-simulating hormone NDP and MT-II | Human melanocortin receptor (hMCR) | Specific marking of surface receptors; Single molecule imaging of GPCR; Multiplexing; Investigating GPCR localization and trafficking in live cells and in single molecule studies | [83]      |
|                     | Deltorphin-II                         | Human δ-opioid receptor (hDOR)   | Monitoring ligand-receptor binding in live cells; Monitoring GPCR internalization; Detecting and labeling several GPCRs in living cells | [53]      |
|                     | ANGII                                | ANGII receptor                   | Monitoring internalization and endosomal trafficking; Identifying two distinct GPCR recycling pathways | [59]      |
|                     | BBN                                  | BBN receptor                     | Monitoring receptor trafficking in rat hippocampal neurons; Suggesting alternative mechanism of mood regulation via GPCR | [85]      |
|                     | HaloTag ligand                        | Cyclic AMP receptor 1 (cAR1)     | Single molecule imaging of GPCR; Using multi-colored, single molecule imaging to study membrane protein dynamics | [56]      |
|                     | Antibody against flag tag (HA)       | Serotonin receptor subtype 1A (5-HT1A) | Monitoring receptor intracellular translocation; Detecting intracellular targets (when conjugated with a cell penetrating agent) | [87]      |
|                     | Antibody against flag tag (HA)       | α- opioid receptors (κ-ORs)       | Displaying receptor affinity and specificity; Monitoring receptor trafficking; Detecting two receptors in one cell; Application in drug screening | [86]      |
|                     | Antibody against flag tag (GFP)      | Adenosine receptor (A2A AR)      | Monitoring receptor trafficking in rat hippocampal neurons; Suggesting alternative mechanism of mood regulation via GPCR | [85]      |
|                     | Antibody against flag tag (GFP)      | Serotonin receptor subtype 1B (5-HT1B) | Monitoring receptor trafficking; Displaying receptor affinity and specificity; Monitoring receptor trafficking; Detecting two receptors in one cell; Application in drug screening | [86]      |
|                     | Antibody against flag tag (GFP)      | k-opioid receptors (κ-ORs)       | Monitoring receptor trafficking; Displaying receptor affinity and specificity; Monitoring receptor trafficking; Detecting two receptors in one cell; Application in drug screening | [86]      |
|                     | Antibody against flag tag (GFP)      | Endothelin A receptor (ET(A)R)   | Monitoring receptor trafficking; Displaying receptor affinity and specificity; Monitoring receptor trafficking; Detecting two receptors in one cell; Application in drug screening | [86]      |
|                     | Antibody against flag tag (HA)       | Serotonin receptor (5-HT1A)      | Single molecule imaging to monitor receptor trafficking; Understanding the mechanism of therapies targeting GPCR | [59]      |
### Table 1. Cont.

| Nanoparticles                  | Ligand/Antibody                        | GPCR                        | Function                                                                 | Reference |
|-------------------------------|----------------------------------------|-----------------------------|--------------------------------------------------------------------------|-----------|
| Gold nanoparticle (AuNP)      | Several AR agonists and antagonists    | Adenosine receptor (AR)     | Affinity to receptor ($K_i$ 37 nM to $A_3A$AR); Cancer diagnosing and treatment | [73]      |
|                               | BBN                                    | Gastrin-releasing peptide receptor (GRPR) | Monitoring receptor internalization; Cancer therapy and molecular imaging in vivo | [74]      |
| Magnetic nanoparticle (MNP)   | Anti-ET$_A$ antibody                   | Endothelin receptor (ET$_A$) | Efficient receptor targeting; Bimodal contrast agent and imaging agent; Targeting tumor pathologies; Early Cancer diagnosing | [32]      |
|                               | MG                                     | Cholecystokinin-2 receptor (CCK2R) | Inducing cell death in cancer | [59]      |
| Elastin-like polypeptide (ELP) micelles | GRP                                    | Gastrin-releasing peptide receptor (GRPR) | Specific receptor targeting; Delivering cytotoxic drugs to cancer | [80]      |
| Unmodified NPs                | FSH                                    | Follicle-Stimulating hormone receptor (FSHR) | Successfully delivering drug to lymph nodes; Reducing metastasis; Ovarian cancer therapy | [79]      |
| Nanorubies                    | Antibody against flag tag (HA)         | $\mu$-opioid receptor       | Imaging functionality; Achieving real-time single molecule imaging on biological samples | [88]      |
3. Conclusions

The GPCR gene family, the largest group of GPCRs, is the molecular target that accounts for almost 30% of FDA-approved drugs [89]. The demand for pharmaceuticals that target GPCRs with good selectivity and enhanced pharmacokinetic qualities, has driven the development of alternative therapies. In GPCR-related cancer treatments and diagnosis, NPs have provided a new mode. NPs have versatile functions. They are used as imaging agents, contrast agents and therapeutic carriers, as well as to induce cell death via endocytosis. As an imaging agent, NPs are able to detect cancer at very early stages, as they are sensitive towards receptors that are only expressed in cancer cells. They have the potential to distinguish cancer cells before the cells migrate and become solid tumors. Early cancer diagnosis is important to prognosis and the outcome of treatment. In addition, NPs are of great value in detecting cancer progression and migration and have proved to be valuable agents in cancer research. In therapeutics, NPs are not only engaged in targeted delivery, but also able to form multivalent ligands with increased receptor binding affinity and avidity, which leads to enhanced pharmacokinetic and pharmacodynamic properties. The applications of NPs in cancer research are expanding with advances in technology and therapeutic strategies.

GPCR signaling regulatory pathways are intricate and complex, but more are yet to be discovered. For this reason, nanoparticle ligand-based complexes represent an alternative approach to the study of GPCRs.

**Funding:** This work and Leo T.O. Lee are supported by FDCT grant (FDCT134/2016/A3) from Macau government and Multi-Year Research Grant (MYRG2018-00161-FHS) from University of Macau.

**Acknowledgments:** We acknowledge Jiao Yufei from Harbin Medical University in helping to prepare this manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

| Acronym | Abbreviation |
|---------|--------------|
| ANGII   | Angiotensin II |
| AR      | Adenosine Receptor |
| AuNP    | Gold Nanoparticle |
| CCK2R   | Cholecystokinin-2 Receptor |
| CXCR4   | Chemokine Receptor 4 |
| EGFR    | Epidermal Growth Factor Receptor |
| ELP     | Elastin-Like Polypeptide |
| EPR     | Enhanced Permeation and Retention Effect |
| ETA     | Endothelin Receptor |
| GLiDe   | GPCR Ligand-Dendrimer |
| GNR     | Gold Nanorod |
| GPCR    | G Protein-Coupled Receptor |
| GRK     | G protein-Coupled Receptor Kinase |
| GRPR    | Gastrin-Releasing Peptide Receptor |
| GTP     | Guanosine Triphosphate |
| 5-HT1A  | Serotonin Receptor Subtype 1A |
| IONP    | Iron Oxide Nanoparticle |
| LPAR    | Lyosphosphatidic Acid Receptor |
| PDGFR   | Platelet-Derived Growth Factor Receptor |
| RTK     | Receptor Tyrosine Kinases |

**References**

1. Bar-Shavit, R.; Maoz, M.; Kancharla, A.; Nag, J.K.; Agranovich, D.; Grisaru-Granovsky, S.; Uziely, B. G Protein-Coupled Receptors in Cancer. *Int. J. Mol. Sci.* **2016**, *17*, 1320. [CrossRef] [PubMed]
2. Munk, C.; Isberg, V.; Mordalski, S.; Harpsoe, K.; Rataj, K.; Hauser, A.S.; Kolb, P.; Bojarski, A.J.; Vriend, G.; Gloriam, D.E. GPCRdb: The G protein-coupled receptor database—An introduction. Br. J. Pharmacol. 2016, 173, 2195–2207. [CrossRef] [PubMed]

3. Kobilka, B.K. G protein coupled receptor structure and activation. Biochim. Biophys. Acta (BBA) Biomembr. 2007, 1768, 794–807. [CrossRef] [PubMed]

4. Luttrell, L.M.; Maudsley, S.; Bohn, L.M. Fulfilling the Promise of “Biased” G Protein-Coupled Receptor Agonism. Mol. Pharmacol. 2015, 88, 579–588. [CrossRef] [PubMed]

5. Vilardaga, J.-P.; Bünemann, M.; Feinstein, T.N.; Lambert, N.; Nikolaev, V.O.; Engelhardt, S.; Lohse, M.J.; Hoffmann, C. Minireview: GPCR and G Proteins: Drug Efficacy and Activation in Live Cells. Mol. Endocrinol. 2009, 23, 590–599. [CrossRef] [PubMed]

6. Bologna, Z.; Teoh, J.-P.; Bayoumi, A.S.; Tang, Y.; Kim, I.-M. Biased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and Pathology. Biomol. Ther. 2017, 25, 12–25. [CrossRef] [PubMed]

7. Delcourt, N.; Bockaert, J.; Marin, P. GPCR-jacking: From a new route in RTK signalling to a new concept in GPCR activation. Trends Pharmacol. Sci. 2007, 28, 602–607. [CrossRef] [PubMed]

8. Pyne, N.J.; Waters, C.M.; Long, J.S.; Moughal, N.A.; Tigyi, G.; Pyne, S. Receptor tyrosine kinase-G-protein coupled receptor complex signaling in mammalian cells. Adv. Enzyme Regul. 2007, 47, 271–280. [CrossRef] [PubMed]

9. Onfroy, L.; Galandrin, S.; Pontier, S.M.; Seguelas, M.H.; N’Guyen, D.; Senard, J.M.; Gales, C. G protein stoichiometry dictates biased agonism through distinct receptor-G protein partitioning. Sci. Rep. 2017, 7, 7885. [CrossRef] [PubMed]

10. Insel, P.A.; Tang, C.-M.; Hahto, T.; Michel, M.C. Impact of GPCRs in clinical medicine: Genetic variants and drug targets. Biochim. Biophys. Acta 2007, 1768, 994–1005. [CrossRef] [PubMed]

11. Liu, Y.; An, S.; Ward, R.; Yang, Y.; Guo, X.-X.; Li, W.; Xu, T.-R. G protein-coupled receptors as promising cancer targets. Cancer Lett. 2016, 376, 226–239. [CrossRef] [PubMed]

12. Nugent, A.; Proia, R.L. The role of G protein-coupled receptors in lymphoid malignancies. Cell. Signal. 2017, 39, 95–107. [CrossRef] [PubMed]

13. Zuckerman, V.; Sokolov, E.; Swet, J.H.; Ahrens, W.A.; Showlater, V.; Iannitti, D.A.; McKillop, I.H. Expression and function of lysophosphatidic acid receptors (LPARs) 1 and 3 in human hepatic cancer progenitor cells. Oncotarget 2016, 7, 2951–2967. [CrossRef] [PubMed]

14. Choi, J.W.; Herr, D.R.; Noguchi, K.; Yung, Y.C.; Lee, C.W.; Mutoh, T.; Lin, M.E.; Teo, S.T.; Park, K.E.; Mosley, A.N.; et al. LPA receptors: Subtypes and biological actions. Annu. Rev. Pharmacol. Toxicol. 2010, 50, 157–186. [CrossRef] [PubMed]

15. Yu, S.; Murph, M.M.; Lu, Y.; Liu, S.; Hall, H.S.; Liu, J.; Stephens, C.; Fang, X.; Mills, G.B. Lysophosphatidic Acid Receptors Determine Tumorigenicity and Aggressiveness of Ovarian Cancer Cells. J. Natl. Cancer Inst. 2008, 100, 1630–1642. [CrossRef] [PubMed]

16. Chow, M.T.; Luster, A.D. Chemokines in Cancer. Cancer Immunol. Res. 2014, 2, 1125–1131. [CrossRef] [PubMed]

17. Braun, L.; Menter, T.; Obermann, E.C.; Knapp, S.; Thommen, S.; Schwaller, J.; Tzankov, A. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma. Br. J. Cancer 2012, 107, 491–500. [CrossRef] [PubMed]

18. Morgat, C.; MacGrogan, G.; Brouste, V.; Velasco, V.; Sevenet, N.; Bonnefoi, H.; Fernandez, P.; Deble, M.; Hindle, E. Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biological, and Clinical Parameters: A Study of 1,432 Primary Tumors. J. Nucl. Med. 2017, 58, 1401–1407. [CrossRef] [PubMed]

19. Laukkanen, M.O.; Castellone, M.D. Gastrin-Releasing Peptide Receptor Targeting in Cancer Treatment: Emerging Signaling Networks and Therapeutic Applications. Curr. Drug Targets 2016, 17, 508–514. [CrossRef] [PubMed]

20. Schwartzmann, G.; DiLeone, L.P.; Horowitz, M.; Schunemann, D.; Cancelli, A.; Pereira, A.S.; Richter, M.; Souza, F.; da Rocha, A.B.; Souza, F.H.; et al. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest. New Drugs 2006, 24, 403–412. [CrossRef] [PubMed]
22. Hu, B.; Cheng, S.-Y. Angiopoietin-2: Development of Inhibitors for Cancer Therapy. *Curr. Oncol. Rep.* 2009, 11, 111–116. [CrossRef] [PubMed]
23. Arafat, H.A.; Gong, Q.; Chipitsyna, G.; Rizvi, A.; Saa, C.T.; Yeo, C.J. Antihypertensives as novel antineoplastics: Angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. *J. Am. Coll. Surg.* 2007, 204, 996–1005, discussion 1005–1006. [CrossRef] [PubMed]
24. Arrieta, O.; Guevara, P.; Escobar, E.; García-Navarrete, R.; Pineda, B.; Sotelo, J. Blockage of angiotensin II type 1 receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. *Br. J. Cancer* 2005, 92, 1247–1252. [CrossRef] [PubMed]
25. Nakai, Y.; Isayama, H.; Ijichi, H.; Sasaki, T.; Takahara, N.; Ito, Y.; Matsubara, S.; Uchino, R.; Yagioka, H.; Arizumi, T.; et al. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. *Investig. New Drugs* 2013, 31, 1294–1299. [CrossRef] [PubMed]
26. Haley, B.; Frenkel, E. Nanoparticles for drug delivery in cancer treatment. *Urol. Oncol.-Semin. Orig. Investig.* 2008, 26, 57–64. [CrossRef] [PubMed]
27. Wicki, A.; Witzigmann, D.; Balasubramanian, V.; Huwyler, J. Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications. *J. Control. Release* 2015, 200, 138–157. [CrossRef] [PubMed]
28. Yameen, B.; Choi, W.I.; Vilos, C.; Swami, A.; Shi, J.J.; Farokhzad, O.C. Insight into nanoparticle cellular uptake and intracellular targeting. *J. Control. Release* 2014, 190, 485–499. [CrossRef] [PubMed]
29. Jain, R.K.; Stylianopoulos, T. Delivering nanomedicine to solid tumors. *Nat. Rev. Clin. Oncol.* 2010, 7, 653–664. [CrossRef] [PubMed]
30. Ulbrich, K.; Holá, K.; Šubr, V.; Bakandritsos, A.; Tuček, J.; Zbořil, R. Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies. *Chem. Rev.* 2016, 116, 5338–5431. [CrossRef] [PubMed]
31. Craig, A.J.; Labgaa, I.; Villacorta-Martin, C.; Ningarhari, M.; Villanueva, A. Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma. In *Resistance to Molecular Therapies for Hepatocellular Carcinoma*; Villanueva, A., Ed.; Springer International Publishing: Cham, Switzerland, 2017.
32. Richard, S.; Boucher, M.; Saric, A.; Herbet, A.; Lalatonne, Y.; Petit, P.X.; Meriaux, S.; Boquet, D.; Motte, L. Optimization of pegylated iron oxide nanoplatforms for antibody coupling and bio-targeting. *J. Mater. Chem. B* 2017, 5, 2896–2907. [CrossRef]
33. Palankar, R.; Pinchasik, B.-E.; Khlebtsov, B.N.; Kolesnikova, T.A.; Möhwald, H.; Winterhalter, M.; Skirtach, A.G. Nanoplasmonically-Induced Defects in Lipid Membrane Monitored by Ion Current: Transient Nanopores versus Membrane Rupture. *Nano Lett.* 2014, 14, 4273–4279. [CrossRef] [PubMed]
34. Zhang, S.L.; Gao, H.J.; Bao, G. Physical Principles of Nanoparticle Cellular Endocytosis. *ACS Nano* 2015, 9, 8655–8671. [CrossRef] [PubMed]
35. Yu, X.J.; Trase, I.; Ren, M.Q.; Duval, K.; Guo, X.; Chen, Z. Design of Nanoparticle-Based Carriers for Targeted Drug Delivery. *J. Nanomater.* 2016, 2016, 1087250. [CrossRef] [PubMed]
36. Lin, J.-T. Modeling the scaling law of surface plasmon resonance in gold spherical nanoshells. *J. Nanophoton.* 2010, 4, 049507. [CrossRef]
37. Fröhlich, E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. *Int. J. Nanomed.* 2012, 7, 5577–5591. [CrossRef] [PubMed]
38. Sheth, S.; Brito, R.; Mukherjea, D.; Rybak, L.P.; Ramkumar, V. Adenosine Receptors: Expression, Function and Regulation. *Int. J. Mol. Sci.* 2014, 15, 2024–2052. [CrossRef] [PubMed]
39. Jacobson, K.A. GPCR ligand-dendrimer (GLiDe) conjugates: Future smart drugs? *Trends Pharmacol. Sci.* 2010, 31, 575–579. [CrossRef] [PubMed]
44. Kim, Y.; Hechler, B.; Klutz, A.M.; Gachet, C.; Jacobson, K.A. Toward Multivalent Signaling across G Protein-Coupled Receptors from Poly(amidoamine) Dendrimers. Bioconjug. Chem. 2008, 19, 406–411. [CrossRef] [PubMed]
45. Kim, Y.; Klutz, A.M.; Hechler, B.; Gao, Z.-G.; Gachet, C.; Jacobson, K.A. Application of the functionalized congener approach to dendrimer-based signaling agents acting through A(2A) adenosine receptors. PPAR Res. 2009, 5, 39–50. [CrossRef] [PubMed]
46. de Castro, S.; Maruoka, H.; Hong, K.; Kilbey, S.M.; Costanzi, S.; Hechler, B.; Brown, G.G.; Gachet, C.; Harden, T.K.; Jacobson, K.A. Functionalized Congeners of P2Y(1) Receptor Antagonists: 2-Alkynyl (N)-Methanocarba 2'-Deoxyadenosine 3',5'-Bisphosphate Analogues and Conjugation to a Polyamidoamine (PAMAM) Dendrimer Carrier. Bioconjug. Chem. 2010, 21, 1190–1205. [CrossRef] [PubMed]
47. Das, A.; Zhou, Y.; Ivanov, A.A.; Carter, R.L.; Harden, T.K.; Jacobson, K.A. Enhanced Potency of Nucleotide–Dendrimer Conjugates as Agonists of the P2Y(14) Receptor: Multivalent Effect in G Protein-Coupled Receptor Recognition. Bioconjug. Chem. 2009, 20, 1650–1659. [CrossRef] [PubMed]
48. Tosh, D.K.; Yoo, L.S.; Chinn, M.; Hong, K.; Kilbey, S.M., 2nd; Barrett, M.O.; Fricks, I.P.; Harden, T.K.; Gao, Z.G.; Jacobson, K.A. Polyamidoamine (PAMAM) dendrimer conjugates of “clickable” agonists of the A3 adenosine receptor and coactivation of the P2Y14 receptor by a tethered nucleotide. Bioconjug. Chem. 2010, 21, 372–384. [CrossRef] [PubMed]
49. Leopoldo, M.; Lacivita, E.; Berardi, F.; Perrone, R. Developments in fluorescent probes for receptor research. Drug Discov. Today 2009, 14, 706–712. [CrossRef] [PubMed]
50. Pisanic, T.R.; Zhang, Y.; Wang, T.H. Quantum dots in diagnostics and detection: Principles and paradigms. Analyst 2014, 139, 2968–2981. [CrossRef] [PubMed]
51. Dong, C.Q.; Huang, X.Y.; Ren, J.C. Characterization of water-soluble luminescent quantum dots by fluorescence correlation spectroscopy. Ann. N. Y. Acad. Sci. 2008, 1130, 253–261. [CrossRef] [PubMed]
52. Yamaguchi, T. Nano-Biomedical Engineering 2012: Proceedings of the Tohoku University Global Centre of Excellence Programme; Imperial College Press: London, UK, 2012.
53. Young, S.H.; Rozengurt, E. Qdot nanocrystal conjugates conjugated to bombesin or ANG II label the cognate G protein-coupled receptor in living cells. Am. J. Physiol. Cell Physiol. 2006, 290, C728–C732. [CrossRef] [PubMed]
54. Michalet, X.; Pinaud, F.F.; Bentolila, L.A.; Tsay, J.M.; Doose, S.; Li, J.J.; Sundaresan, G.; Wu, A.M.; Gambhir, S.S.; Weiss, S. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005, 307, 538–544. [CrossRef] [PubMed]
55. Hild, W.; Pollinger, K.; Caporale, A.; Cabrele, C.; Keller, M.; Pluym, N.; Buschauer, A.; Rachel, R.; Tessmar, J.; Breunig, M.; et al. G protein-coupled receptors function as logic gates for nanoparticle binding and cell uptake. Proc. Natl. Acad. Sci. USA 2010, 107, 10667–10672. [CrossRef] [PubMed]
56. KomatsuSuzuki, A.; Ohyanagi, T.; Tsukasaki, Y.; Miyanaga, Y.; Ueda, M.; Jin, T. Halo-Ligand-Conjugated Quantum Dots for Multicolored Single-Molecule Imaging of Overcrowding GPCR Proteins on Cell Membranes. Small 2015, 11, 1396–1401. [CrossRef] [PubMed]
57. Ji, X.J.; Zheng, J.Y.; Xu, J.M.; Rastogi, V.K.; Cheng, T.C.; DeFrank, J.J.; Leblanc, R.M. (CdSe)ZnS quantum dots and organophosphorus hydrolase bioconjugate as biosensors for detection of paraoxon. J. Phys. Chem. B 2005, 109, 3793–3799. [CrossRef] [PubMed]
58. Hennig, R.; Pollinger, K.; Tessmar, J.; Goepferich, A. Multivalent targeting of AT(1) receptors with angiotensin II-functionalized nanoparticles. J. Drug Target. 2015, 23, 681–689. [CrossRef] [PubMed]
59. Fichter, K.M.; Flajolet, M.; Greengard, P.; Vu, T.Q. Kinetics of G-protein-coupled receptor endosomal trafficking pathways revealed by single quantum dots. Proc. Natl. Acad. Sci. USA 2010, 107, 18658–18663. [CrossRef] [PubMed]
60. Dreaden, E.C.; Mackey, M.A.; Huang, X.H.; Kang, B.; El-Sayed, M.A. Beating cancer in multiple ways using nanogold. Chem. Soc. Rev. 2011, 40, 3391–3404. [CrossRef] [PubMed]
61. Huang, X.H.; Peng, X.H.; Wang, Y.Q.; Wang, Y.X.; Shin, D.M.; El-Sayed, M.A.; Nie, S.M. A Reexamination of Active and Passive Tumor Targeting by Using Rod-Shaped Gold Nanocrystals and Covalently Conjugated Peptide Ligands. ACS Nano 2010, 4, 5887–5896. [CrossRef] [PubMed]
62. Khlebtsov, N.; Dykman, L. Biodistribution and toxicity of engineered gold nanoparticles: A review of in vitro and in vivo studies. Chem. Soc. Rev. 2011, 40, 1647–1671. [CrossRef] [PubMed]
63. Patra, C.R.; Bhattacharya, R.; Mukhopadhyay, D.; Mukherjee, P. Application of gold nanoparticles for targeted therapy in cancer. *J. Biomed. Nanotechnol.* 2008, 4, 99–132. [CrossRef]  
64. Shukla, R.; Bansal, V.; Chaudhary, M.; Basu, A.; Bhonde, R.R.; Sastry, M. Biocompatibility of Gold Nanoparticles and Their Endocytotic Fate Inside the Cellular Compartment: A Microscopic Overview. *Langmuir* 2005, 21, 10644–10654. [CrossRef] [PubMed]  
65. DeLong, R.K.; Reynolds, C.M.; Malcolm, Y.; Schaeffer, A.; Severs, T.; Wanekaya, A. Functionalized gold nanoparticles for the binding, stabilization, and delivery of therapeutic DNA, RNA, and other biological macromolecules. *Nanotechnol. Sci. Appl.* 2010, 3, 53–63. [CrossRef] [PubMed]  
66. El-Sayed, I.H.; Huang, X.; El-Sayed, M.A. Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: Applications in oral cancer. *Nano Lett.* 2005, 5, 829–834. [CrossRef] [PubMed]  
67. Liu, J.; Peng, Q. Protein-gold nanoparticle interactions and their possible impact on biomedical applications. *Acta Biomater.* 2017, 55, 13–27. [CrossRef] [PubMed]  
68. Yeh, Y.-C.; Creran, B.; Rotello, V.M. Gold Nanoparticles: Preparation, Properties, and Applications in Bionanotechnology. *Nanoscale* 2012, 4, 1871–1880. [CrossRef] [PubMed]  
69. Qin, Z.; Bischof, J.C. Thermophysical and biological responses of gold nanoparticle laser heating. *Chem. Soc. Rev.* 2012, 41, 1191–1217. [CrossRef] [PubMed]  
70. Xiong, R.; Raemdonck, K.; Peynshaert, K.; Lentacker, I.; De Cock, I.; Demeeuster, J.; De Smedt, S.C.; Skirtach, A.G.; Braeckmans, K. Comparison of Gold Nanoparticle Mediated Photoporation: Vapor Nanobubbles Outperform Direct Heating for Delivering Macromolecules in Live Cells. *ACS Nano* 2014, 8, 6288–6296. [CrossRef] [PubMed]  
71. Delcea, M.; Sternberg, N.; Yashchenok, A.M.; Georgieva, R.; Baumler, H.; Mohwald, H.; Skirtach, A.G. Nanoplasmonics for dual-molecule release through nanopores in the membrane of red blood cells. *ACS Nano* 2012, 6, 4169–4180. [CrossRef] [PubMed]  
72. Skirtach, A.G.; Dejugnat, C.; Braun, D.; Susha, A.S.; Rogach, A.L.; Parak, W.J.; Mohwald, H.; Sukhorukov, G.B. The role of metal nanoparticles in remote release of encapsulated materials. *Nano Lett.* 2005, 5, 1371–1377. [CrossRef] [PubMed]  
73. Jayasekara, P.S.; Phan, K.; Tosh, D.K.; Kumar, T.S.; Moss, S.M.; Zhang, G.F.; Barchi, J.J.; Gao, Z.G.; Jacobson, K.A. Modulation of G protein-coupled adenosine receptors by strategically functionalized agonists and antagonists immobilized on gold nanoparticles. * Purinergic Signal.* 2013, 9, 183–198. [CrossRef] [PubMed]  
74. Nripen, C.; Shukla, R.; Katti, K.V.; Kannan, R. Gastrin Releasing Protein Receptor—Specific Gold Nanorods: Breast and Prostate Tumor-avid Nanovectors for Molecular Imaging. *Nano Lett.* 2009, 9, 1798–1805. [CrossRef]  
75. Arruebo, M.; Fernández-Pacheco, R.; Ibarra, M.R.; Santamaría, J. Magnetic nanoparticles for drug delivery. *Nano Today* 2007, 2, 22–32. [CrossRef]  
76. Bañobre-López, M.; Teijeiro, A.; Rivas, J. Magnetic nanoparticle-based hyperthermia for cancer treatment. *Rep. Pract. Oncol. Radiother.* 2013, 18, 397–400. [CrossRef] [PubMed]  
77. Gobbo, O.L.; Sjaastad, K.; Radomski, M.W.; Volkov, Y.; Prina-Mello, A. Magnetic Nanoparticles in Cancer Theranostics. *Theranostics* 2015, 5, 1249–1263. [CrossRef] [PubMed]  
78. Sanchez, C.; El Hajj Diab, D.; Connord, V.; Clerc, P.; Meunier, E.; Pipy, B.; Payré, B.; Tan, R.P.; Gougeon, M.; Carrey, J.; et al. Targeting a G-Protein-Coupled Receptor Overexpressed in Endocrine Tumors by Magnetic Nanoparticles To Induce Cell Death. *ACS Nano* 2014, 8, 1350–1363. [CrossRef] [PubMed]  
79. Fan, L.; Chen, J.; Zhang, X.; Liu, Y.; Xu, C. Follicle-stimulating hormone polypeptide modified nanoparticle drug delivery system in the treatment of lymphatic metastasis during ovarian carcinoma therapy. *Gynecol. Oncol.* 2014, 135, 125–132. [CrossRef] [PubMed]  
80. Zhang, W.; Garg, S.; Eldi, P.; Zhou, F.H.-h.; Johnson, I.R.D.; Brooks, D.A.; Lam, F.; Rychkov, G.; Hayball, J.; Albrecht, H. Targeting prostate cancer cells with genetically engineered polypeptide-based micelles displaying gastrin-releasing peptide. *Int. J. Pharm.* 2016, 513, 270–279. [CrossRef] [PubMed]  
81. Kecskes, A.; Tosh, D.K.; Wei, Q.; Gao, Z.G.; Jacobson, K.A. GPCR Ligand Dendrimer (GLiDe) Conjugates: Adenosine Receptor Interactions of a Series of Multivalent Xanthine Antagonists. *Bioconj. Chem.* 2011, 22, 115–1127. [CrossRef] [PubMed]
82. Kim, Y.; Hechler, B.; Gao, Z.L.; Gachet, C.; Jacobson, K.A. PEGylated Dendritic Unimolecular Micelles as Versatile Carriers for Ligands of G Protein-Coupled Receptors. *Bioconj. Chem.* 2009, 20, 1888–1898. [CrossRef] [PubMed]

83. Zhou, M.; Nakatani, E.; Gronenberg, L.S.; Tokimoto, T.; Wirth, M.J.; Hruby, V.J.; Roberts, A.; Lynch, R.M.; Ghosh, I. Peptide-labeled quantum dots for imaging GPCRs in whole cells and as single molecules. *Bioconj. Chem.* 2007, 18, 323–332. [CrossRef] [PubMed]

84. Thurner, P.; Gsandtner, I.; Kudlacek, O.; Choquet, D.; Nanoff, C.; Freissmuth, M.; Zezula, J. A Two-state Model for the Diffusion of the A(2A) Adenosine Receptor in Hippocampal Neurons. *J. Biol. Chem.* 2014, 289, 9263–9274. [CrossRef] [PubMed]

85. Liebmann, T.; Kruusmagi, M.; Sourial-Bassillious, N.; Bondar, A.; Svenningsson, P.; Flajolet, M.; Greengard, P.; Scott, L.; Brismar, H.; Aperia, A. A Noncanonical Postsynaptic Transport Route for a GPCR Belonging to the Serotonin Receptor Family. *J. Neurosci.* 2012, 32, 17998–18008. [CrossRef] [PubMed]

86. Lee, J.; Kwon, Y.J.; Choi, Y.; Kim, H.C.; Kim, K.; Kim, J.; Park, S.; Song, R. Quantum Dot-Based Screening System for Discovery of G Protein-Coupled Receptor Agonists. *ChemBioChem* 2012, 13, 1503–1508. [CrossRef] [PubMed]

87. Choi, Y.; Kim, K.; Hong, S.; Kim, H.; Kwon, Y.J.; Song, R. Intracellular Protein Target Detection by Quantum Dots Optimized for Live Cell Imaging. *Bioconj. Chem.* 2011, 22, 1576–1586. [CrossRef] [PubMed]

88. Sreenivasan, V.K.A.; Wan Razali, W.A.; Zhang, K.; Pillai, R.R.; Saini, A.; Denkova, D.; Santiago, M.; Brown, H.; Thompson, J.; Connor, M.; et al. Development of Bright and Biocompatible Nanoruby and Its Application to Background-Free Time-Gated Imaging of G-Protein-Coupled Receptors. *ACS Appl. Mater. Interfaces* 2017, 9, 39197–39208. [CrossRef] [PubMed]

89. Overington, J.P.; Al-Lazikani, B.; Hopkins, A.L. How many drug targets are there? *Nat. Rev. Drug Discov.* 2006, 5, 993–996. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).